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The proteome is in a dynamic equilibrium of synthesis and degradation.  Although, 
synthesis plays an important role in controlling the steady state concentration of some proteins, 
degradation pathways provide an equally important contribution to regulating protein turnover.  
The two major cellular degradation pathways are the lysosomes and the ubiquitin proteasome 
system (UPS).  Lysosomes degrade mostly endocytosed membrane proteins.  In contrast, the 
ubiquitin proteasome system is responsible for degradation of the majority of intracellular 
proteins (up to 80-90% of all intracellular proteins in mammalian cells) (1), which include not 
only damaged, misfolded, or aged proteins, but also many proteins vital to eukaryote biology 
such as those involved in the cell cycle and transcriptional regulation (2-4).  The degradation 
process of the UPS is divided into two steps.  First, intracellular proteins are marked for 
degradation through the covalent linkage of a string of ubiquitin molecules.  Ubiquitin is a highly 
conserved 76 amino acid sequence that is linked to lysine residues of selected proteins through 
an enzymatic cascade involving E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating 
enzyme) and E3 (ubiquitin ligase) (5).  A polyubiquitin chain is then assembled onto the targeted 
protein via an isopeptide linkage between the lysine residue of the previous ubiquitin and the C-
terminal glycine residue of the subsequently attached ubiquitin.   
The second step of the ubiquitin degradation pathway involves the 26S proteasome 
complex that contains the proteolytic activity that catalyzes the degradation of polyubiquitinated 
proteins.  The 26S proteasome complex is composed of the 20S proteolytic core and the 19S 
activation complex, which is situated on one or both ends of the 20S proteasome (13).  The 20S 
proteasome is a cylindrical-barrel shaped complex containing 28 subunits arranged in two α and 
two β rings with α1-7, β1-7, β1-7, and α1-7 symmetry (Figure 1).  The proteolytic activity of the 
 3 
UPS resides in three β subunits, specifically the β1, β2, and β5 subunits.  In general, the three 
main proteolytic activities that have been ascribed to the proteasome include:  caspase-like (β1), 
trypsin-like (β2), and chymotrypsin-like (β5) activity.  Flanking the inner β core on both sides is 
a ring of α subunits that do not maintain any proteolytic activity.  However, crystallographic 
structural analysis of the proteasome shows that these α subunits partially prevent substrate 
access to the central chamber by forming the α annulus that projects into the openings at either 
end of the cylinder (6-8).  Despite this partial blockage, the 20S proteasome can degrade any 
protein that is able to enter the central chamber, however degradation remains relatively 
inefficient. 
 The inefficient degradation by the 20S proteasome is overcome when one or two 19S 
complexes bind on one or both sides of the 20S forming the active 26S proteasome.  The 19S 
complex consists of 17 subunits that form two distinct subcomplexes: the base and the lid.  The 
base is composed of six ATPase subunits (Rpt1-Rpt6) and two larger non-ATPase subunits 
(Rpn1and Rpn2) (Figure 1).  The six ATPase subunits form a ring that sits on top of the outer α 
ring (6, 9).  The primary functions of the base include: activating the 20S proteasome by 
rearranging the α annulus, hydrolyzing ATP to unfold substrate proteins so they can be 
translocated through the central channel of the 20S proteasome, and providing an attachment 
point for the 19S lid (10-11).  The lid complex is composed of the remaining nine subunits of the 
19S and possesses the Rpn 10 subunit which is responsible for recognition of polyubiquinated 
proteins and the Rpn 11 subunit that deubiquitinates substrates prior to their passage into the 20S 
core in an ATP dependent manner (12).  Additionally, the 20S can associate with the 11S 
activator complex (PA28α, PA28β, and PA28γ) at one or both ends which promotes proteolytic 
degradation in an ubiquitin and ATP independent manner. 
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Even though assembly and stability of the 20S proteolytic core with the 19S or 11S 
provides one manner for regulation of the UPS degradation pathway, post-translational 
modifications also offer another level of control.  Recent work by Zong et al. described novel 
phosphorylation patterns on the 20S complex and identified two associating partners, protein 
kinase A (PKA) and protein phosphatase 2A (PP2A) (14).  They also showed that in vitro 
administration of PKA increased the overall proteolytic activity and increased the 
phosphorylation of certain 20S subunits.  Additional support for the importance of PKA-
mediated regulation of the proteasome was provided by Zhang et al. who showed that PKA 
phosphorylation of the 19S ATPase Rpt6 subunit was important for activation of the proteasome 
in vitro (13). 
Besides phosphorylation, oxidation has also been shown to have an equally important 
effect on the UPS.    The UPS is responsible for degrading most oxidized proteins, however 
under conditions of intense oxidative stress the accumulation of oxidized proteins overwhelm the 
functional capacity of the UPS resulting in the formation of insoluble oxidized protein 
aggregates and overall UPS impairment (32, 33).  In addition, oxidative modification to the 
proteasome itself has been shown to inhibit proteasomal function (34).  Overall, modifications 
including oxidation and phosphorylation have been shown to affect the stability, activity, and 
assembly of the 26S proteasome and provide vital dynamic responses to cell signals and stresses 
(9, 13-16).      
 
Role of the 26S Proteasome in Cardiac Diseases 
Dysfunction of the UPS has been well characterized in a variety of human disorders 
including neurodegenerative disorders, cataracts, and muscle atrophy (17-20).  However, 
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investigations into the relationship between the UPS and cardiovascular diseases are only 
beginning to emerge.  Previous animal studies have reported UPS dysfunction in a desmin-
related cardiomyopathy through the accumulation of protein aggregates and the depletion of key 
components within the 19S (21).  In addition, animal models of myocardial ischemia have shown 
increased oxidation of the proteasome resulting in decreased proteolytic activity and an increase 
in the cellular accumulation of ubiquitinated substrates (22, 23).  Lastly, a recent study on a 
genetic animal model of cardiomyopathy suggested that truncation mutations in cardiac myosin 
binding protein C (cMyBP-C) competitively inhibit the degradation of UPS substrates and may 
be a contributing factor to the pathogenesis of familial hypertrophic cardiomyopathy (25).  
Familial hypertrophic cardiomyopathy is the most common heritable cardiovascular disease 
affecting 1 in 500 individuals and is primarily caused by heterozygous mutations in sarcomere 
genes.  Hypertrophic cardiomyopathy is characterized by cardiac hypertrophy and a broad 
clinical spectrum that includes heart failure, arrhythmias, and sudden cardiac death.  Yet overall, 
studies in animal models of cardiac hypertrophy are in disagreement showing both inhibition and 
activation of the UPS (26-28).  Limited data are available on the relationship between the UPS 
and human cardiac hypertrophy.   
The current work seeks to investigate protein degradation and turnover by the UPS in 
cardiac muscle diseases using both human cardiac tissue and a mouse model of myocardial 
infarction.  The first half of the study investigates UPS activity in different human cardiac 
disease states: end-stage heart failure (F) and hypertrophic cardiomyopathy (HCM).  We found a 
significant reduction in proteasomal activity in both F and HCM tissue in comparison to non-
failing controls.  In addition, HCM patients who carried mutations in myofilament genes had 
significantly lower proteasome activity compared with HCM patients lacking pathogenic 
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mutations.  These results are particularly interesting given a previous study that showed that a 
HCM-associated cMyBP-C truncation mutation impaired UPS function (25).  I have begun to 
investigate the hypothesis that cMyBP-C mutations could impair UPS activity in human tissue 
by altering the tight stoichiometry normally maintained by the sarcomere. I found that overall 
protein expression level of cMyBP-C was significantly reduced in samples containing MYBPC3 
mutations.  I have also begun to study the stoichiometric ratios of mutant and wild-type MyBPC 
and other sarcomere proteins in human samples, with the intent to learn how mutations in these 
proteins affect their stability and interactions with their wild-type partners.          
Finally in the second half of this study, we investigated the effects of myocardial 
infarction on UPS function.  In contrast to what was observed in human heart tissue, we found 
that proteasomal activity was significantly increased in infarcted hearts two weeks after left 
coronary artery ligation.  Yet, I did not observe an increase in content of subunits from the 20S 
core, the 19S regulatory cap, or the 11S activator.  The activation of the proteasome could be 
explained through posttranslational modifications for which I developed an immunoprecipatation 
protocol coupled with LC/MS/MS analysis to analyze differential phosphorylation.  My 
investigations show that phosphorylation of the α-7 (43), previously shown to be important to the 
stability of the 26S complex, was not significantly different in mice following myocardial 
infarction.  Current research is underway to study phosphorylation differences in other 
proteasomal subunits following myocardial infarction. 
 
METHODS 
Human heart tissue procurement: Tissue from non-failing, failing, and HCM hearts was 
collected as described in Predmore et al (24). Tissue collection from human hearts used in this 
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study has the approval of the University of Michigan Institutional Review Board (IRB) and 
subjects gave informed consent.   
 
Chemicals and reagents: Fluorogenic substrates Suc-LLVY-AMC and Z-LLE-AMC, 
proteasome inhibitor lactacystin, and all antibodies used to detect proteasome subunits and 
polyubiquinated proteins were from Biomol International (Plymouth Meeting, PA).  Antibodies 
for rabbit and mouse GAPDH were from Abcam and Chemicon respectively.  The antibody 
raised against the first 14 amino acids of cMyBP-C was kindly provided by Sakthivel 
Sadayappan.  The antibody designed to recognize substrates of PKA dependent phosphorylation 
was acquired from Cell Signaling.  ProQ Diamond phosphor stain (Molecular Probes) and 
SYPRO RUBY protein stain (Bio-Rad) were also used for detection of phosphorylated proteins 
and total protein, respectively.  
 
 Proteasome activity assay: Chymotrypsin-like and caspase-like activity of the proteasome from 
cardiac tissue was measured using an optimized procedure outlined by Predmore et al (24). 
 
Immunoblotting and densitometry analysis:  Protein concentration was determined by the 
Bradford method. Protein extracts were denatured by boiling and sonication, resolved by SDS-
PAGE, transferred to nitrocellulose membranes, and blocked in 5% milk. Blots were probed with 
primary antibodies for 1-18 hours, followed by fluorescent-tagged secondary antibodies for 1 
hour. Imaging and densitometry analyses were performed using the LI-COR Odyssey laser 
scanner or ImageQuant TL software and band intensity was normalized to GAPDH as a protein 
loading control unless otherwise specified. 
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Quantitative mRNA analysis: The quantification of cMyBP-C mRNAs was performed by two 
step RT-PCR coupled with Taqman hydrolysis probes.  Total RNA was extracted from human 
tissue using the RNeasy kit (Qiagen) according to the manufacturer’s instructions.  RNA 
concentration, purity, and quality were determined using Biophotometer Plus (Eppendorf).  RT 
was performed using Omniscript RT kit (Qiagen) according to manufacturer’s instructions and 
cDNA concentration was determined by the Biophotometer Plus.  A Taqman hydrolysis probe 
specifically recognizing the exon 2-3 junction with human cMyBP-C was used for quantification 
of mRNA transcripts (Applied Biosystems).  β-actin was used as an endogenous referent gene.  
Experiments were performed on the 7000 Sequence Detection System (Applied Biosystems).  
The relative mRNA amount was estimated according to the comparative Ct method with the      
2-ΔΔCt formula in comparison to non-failing control samples.    
 
Absolute Quantification of Abundance (AQUA):  In collaboration with NextGen Inc., the ratio of 
mutant to wild type proteins in human tissue heterozygous for the cMyBP-C R495Q mutation 
was calculated by engineering peptides corresponding to a specific wild-type peptide sequence 
(DGVELTREETFK) and a specific mutant peptide sequence (DGVELTQEETFK).  These 
AQUA peptides were synthesized with isotopically enriched Lysine containing 13C and 15N.  
Purity of both stable-isotopelabeled peptides was verified by HPLC.  The masses of the isotope-
labeled peptides were measure by MALDI-TOD-MS.  Endogenous peptides were obtained by 
performing a myofilament preparation on human cardiac tissue as described in Wolff et al. (48) 
and separating the myofilament proteins using SDS-PAGE.  The cMyBP-C band of interest was 
identified and gel excised.  The band was digested by reducing with DTT at 60oC then allowing 
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the solution to cool to room temperature followed by alkylation with iodoacetamide.  The 
endogenous sample was then incubated at 37oC for 4 hr in Lys-C (creating wild type and mutant 
peptides the same length as the synthesized peptides) and the reaction was stopped with formic 
acid.  The supernatant was then analyzed directly.  A 38µl aliquot of the supernatant was spiked 
with 2 µl of 10fmol/µl of AQUA peptide (to yield 0.5 fmol/µl in the sample).  A 10µl injection 
of the sample was then analyzed on a LC chromograph with peak areas calculated using Thermo 
Qual Browser software.  After, the ratio of peak areas for the light peptide (endogenous peptide) 
and heavy peptide (AQUA peptide) was calculated and exact amounts of mutant and wild type 
peptides determined based on the known quantity of AQUA peptide injected.  
 
LCA Ligation Model: Heart failure in mice age 3 to 4 months was induced through permanent 
left coronary artery ligation performed by Dr. Sharlene Day as previously described (31).  Hearts 
were harvested after 2 weeks, which was the time point of maximal proteasome activation. 
 
Proteasome Immunoprecipation:  Tissue homogenates were prepared in 1X RIPA buffer 
(Millipore) supplemented with 1nM Calyculin A, 1mM Sodium Orthovanadate, 1 mM sodium  
fluoride, 1  µg/mL aprotinin, 1 µg/mL leupeptin, and 1 µg/mL pepstatin and incubated at 4oC for 
30 minutes.  The homogenates were centrifuged at 14,000xg for 10 minutes and the supernatant 
removed.  The supernatant was pre-cleared by adding 100 µl of Protein A Sepharose beads and 
shaking for 1 hour at 4oC.  The protein concentration of the supernatant was determined using 
the Bradford method and then diluted to 4 µg/mL in PBS.  To immunoprecipitate the 
proteasome, the supernatant was incubated with 2.5 µl of rabbit anti-Rpt-6 (Biomol), for 
purification of the 19S proteasome, or rabbit anti-α-3 (custom antibody), for purification of the 
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20S proteasome antibody overnight at 4oC.  The immunocomplex was collected by adding 100 
µl of Protein A Sepharose beads to the sample and incubating for 1 hour after which the sample 
was centrifuged at 3000xg for 10 minutes.  After removing the supernatant, the pellet was 
washed three times in 1X PBS.  The proteasome-bound Protein A Sepharose beads were 
incubated in laemmli buffer for 5 minutes at 100oC.  The samples were centrifuged at 5000xg 
and the supernatant containing the proteasome was collected for analysis. 
 
2-Dimensional Gel Analysis:  For 2-Dimensional gel electrophoresis (2DE), purified 26S 
proteasomal complex was lyophilized from laemmli buffer and resuspended in IPG rehydration 
buffer.  pH strips 4-10 (Bio-Rad) were rehydrated in this solution and the sample was then 
separated on the Bio-Rad 2D electrophoresis system.  After IEF, IPG strips were reduced by 2% 
DTT solution and alkylated by 2.5% iodoacetic acid (IAA) sequentially for 10 minutes each.  
The second dimension electrophoresis was done on Bio-Rad precast Criterion gel (12.5%).  The 
resulting 2D gel was either stained with SYPRO RUBY and used in LC/MS/MS application or 
transferred to nitrocellulose membrane for western blotting.   
 
LC/MS/MS Analysis and Defining Phosphorylation of Proteasome Subunits:  Enriched 26S 
proteasome preparations were separated by SDS-PAGE.  Regions of interest were identified 
based on molecular weight of the proteasome and these regions were excised into seven equal 
segments.  Each segment was digested with trypsin and analyzed using LC/MS/MS with a 1 hour 
gradient on the LTQ Orbitrap XL mass spectrometer.  The resulting product ion data were 
searched against the forward and reverse IPIMouse v3.60 protein database.  The database was 
appended with commonly observed background proteins to prevent false assignment of peptides 
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derived from those proteins.  Spectral count per protein were collected and reflect the number of 
matched peptides and the number of times those peptides were observed.  Spectral counts were 
normalized to TnI (20S subunits) and actin (19S subunits) to allow for between group 
comparisons.  Phosphopeptide enrichment and analysis using TiO2 was performed as described 
in Lu et al. (42).   
   
Statistical analysis: Data are expressed as mean ± SEM unless otherwise indicated. Continuous 
variables were analyzed using 1-way ANOVA. 26S proteasome activity over a range of ATP 
concentrations was analyzed using 2-way repeated-measures ANOVA with Bonferroni 
adjustment for multiple comparisons. All statistical analysis was performed using Sigma Stat 3.0 
or Microsoft Excel with P<0.05 indicating significant differences. 
 
 
PART 1 RESULTS: The effects of sarcomere gene mutations on UPS function in 
hypertrophic cardiomyopathy (HCM)  
 
Impairment of UPS activity in HCM and failing hearts compared to non-failing controls 
 Cardiac tissue was collected from hypertrophic cardiomyopathy (HCM), end-stage heart 
failure (F), and non-failing patients (NF).  As expected, the HCM patients displayed remarkable 
LV wall thickness presenting a maximum wall thickness that was significantly increased in 
comparison to NF or F patients.  In addition, HCM patients exhibited a significant increase in 
ejection fraction and systolic function, while F patients exhibited a significant decrease in 
ejection fraction and systolic function, in comparison to NF cardiac tissue (see ref 24 for 
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additional details on patient demographics).  For the 29 HCM patients, 22 chose to undergo 
genetic testing and 14 of these 22 exhibited a pathogenic sarcomere gene mutations that has 
previously been reported to correlate with HCM.  Within the HCM group, genetic testing 
identified mutations in MYBPC3 (n=12), TNNT2 (n=1), and TPM1 (n=1).   
Prior to my entry into the lab, chymotrypsin-like and caspase-like activity of the UPS was 
analyzed by Jaime Predmore in HCM, F, and NF tissue over a range of ATP concentrations 
using a synthetic fluorogenic peptides as substrates.  Total chymotrypsin-like activity was 
significantly decreased in HCM and F samples in comparison to NF samples over the entire 
range of ATP (p<0.001, Figure 2A).  Similarly, total caspase-like activity was markedly 
decreased in HCM and F compared to NF tissue at basal ATP and all exogenous ATP 
concentrations (Figure 2B).  In addition, in order to more fully access the impairment of UPS the 
accumulation of polyubiquinated proteins in tissue homogenates was analyzed.  Both HCM and 
F tissue showed an increase in the presence of polyubiquinated proteins compared to non-failing 
tissue, but only the increase in the F tissue was significant (p<0.05, Figure 2D and E) (24).  
 
Proteasome subunit composition not altered in HCM and F compared to NF 
 There are several ways to explain the observed impairment of proteasomal activity in 
HCM and F tissue.  One such explanation involves overall down regulation of proteasomal 
subunits.  Therefore representative subunit expression was evaluated for the 20S, 19S, and 11S 
complexes.  Upon investigation there was no significant difference in proteasomal subunit 
expression for α-7 (20S), Rpt-4, Rpt-1, Rpt-3, (19S ATPases), Rpt-10 (19S ubiquitin recognition 
site) and PA28α (11S) in HCM and F tissue compared to the NF control (Figure 3). These data 
suggest that the impairment of proteasome activity in HCM and F tissue cannot be explained by 
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a decrease in proteasomal subunit expression and led us to hypothesize that is was instead post-
translational modifications to the proteasome.  Recently published work in our lab suggests that 
oxidative modification plays an important role in regulating the activity of the UPS is F tissue 
(24), yet a mechanistic explanation for the observed decrease in UPS activity in HCM tissue 
remains in question.  
 
Lower UPS activity in HCM samples with sarcomere mutations and decreased cMyBP-C 
expression in HCM samples with a variety of cMyBP-C mutations: 
Over half of the cases of HCM are linked to mutations in myofilament genes.  When 
comparing within the HCM group, chymotrypsin-like activity of HCM samples with pathogenic 
myofilament gene mutations showed markedly lowered activity than HCM samples without 
pathogenic mutations (Figure 4A).  This finding is very intriguing given the results of a recent 
study, which shows that accelerated degradation of truncated mutants of the myofilament 
protein, cMyBP-C, impair the functional capabilities of the UPS in neonatal rat cardiac myocytes 
(25).  cMyBP-C is a 140-kDa protein that belongs to the intracellular immunoglobin super 
family and, like other sarcomeric proteins is composed of repeating Ig and fibonectin type-3 
domains.  The cardiac isoform of MyBP-C differs from the skeletal form as the cardiac form 
possesses an extra Ig region (C0) and a phosphorylation domain (M) in between C1 and C2 
(Figure 4B).  Prior work has shown that cMyBP-C associates with the thin and thick filaments 
within the cardiac sarcomere and some evidence shows that cMyBP-C plays a role in myofibril 
assembly and organization (38).  
We hypothesize that instability of mutant proteins within the sarcomere could lead to 
UPS dysfunction and have begun to study this relationship by investigating human heart tissue 
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from HCM patients who displayed one of the following cMyBP-C mutations:  6 premature 
truncations, 2 spice site variations, 2 inframe duplications or deletions, and 2 missense allele 
(Glu542Gln and Arg495Gln)  (Figure 4B).  In these samples, the absolute content of cMyBP-C 
protein was significantly reduced in hearts containing both truncated and full-length MYBPC3 
mutations (normalized densitometric ratio 61% ± 6) vs. human non-failing hearts (93% ± 8, 
p<0.05) or HCM hearts lacking sarcomere mutations (115% ± 12, p<0.01) (Figure 4C and D).  
However, no truncated mutant cMyBP-C proteins were detected by immunoblotting using an 
antibody that recognizes an N-terminal epitope of cMyBP-C.  Interestingly, a single HCM 
patient who exhibited a cMyBP-C truncation (IVS20 2A>G) and progressed to end stage heart 
failure requiring a left ventricular assist device showed the lowest cMyBP-C expression of all 
tested samples.  In contrast, total cMyBP-C expression was not reduced in other end stage failing 
heart samples of diverse etiologies (Figure 4E) suggesting that the observed decrease in cMyBP-
C expression in IVS20 2A>G is not a consequence of the progression to heart failure. 
 
mRNA expression levels within HCM samples with cMyBP-C mutations 
 The decrease in amount of total cMyBP-C expression in HCM samples with cMyBP-C 
mutations could be the result of decreased mRNA expression or transcript instability or 
accelerated protein degradation.  I found that the total amount of mature cMyBP-C mRNA 
transcripts in the HCM tissue compared to non-failing donor control tissue was not significantly 
reduced (Figure 5).  Interestingly, some individual samples did display a reduction in mRNA 
expression levels in comparison to the non-failing donor control, but the degree of reduction was 
far less than the overall reduction in cMyBP-C observed at the protein level suggesting that post 
translational protein processing may also contribute to the decrease in cMyBP-C expression. 
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In addition, I also sought to investigate the relative percentages of wild type and mutant 
mRNA transcripts within HCM samples with cMyBP-C mutations.  Nonsense-mediate mRNA 
decay (NMD) specifically targets premature truncation(PTC)-bearing mRNAs for degradation 
when the PTC lies >50 to 55 nt upstream of the last exon-exon junction, which is the case with 
all the truncation mutations samples we have collected.  Thereby, if NMD was degrading the 
truncation products at the mRNA level, this would explain why I failed to see the truncated 
mutant cMyBP-C at the protein level.  To characterize the levels of different cMyBP-C mutant 
mRNAs, I created Taqman hydrolysis probes to recognize mutant mRNA or total cMyBP-C 
mRNA, and from these two assays, the percentage of mutant and wild type transcript could be 
calculated.  I found that different sets of primer/probe did not amplify cMyBP-C cDNA with 
equal efficiencies and therefore I did not feel confident that I would be able to accurately 
quantify the relative amount of mutant and wild type mRNA transcripts in our HCM samples.  
Adjusting the primer/probe concentrations in the reactions did not significantly affect reaction 
efficiency, so I am currently working on adjusting the cDNA concentration to equalize 
efficiencies of each individual primer/probe set for each individual sample.  
 
Quantification of the relative ratio of mutant and wild-type proteins in cMyBP-C R495Q 
missense mutations: 
 Another potential cellular mechanism that may contribute to the observed decrease in 
total cMyBP-C protein expression is degradation of the mutant proteins by the UPS.  Previous 
studies in in vitro and animal model systems, along with limited data in human HCM hearts, 
have led to the widely accepted hypothesis that sarcomere gene mutations that result in 
premature truncations (>50% of MyBPC3) cause haploinsufficiency (35-37), while missense 
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mutations in full-length proteins (majority of non-MyBPC3 mutations) exert their effects through 
a dominant-negative mechanism, maintaining sarcomere protein stoichiometry. In the latter case, 
the conventional belief is that the ratio of mutant to wild-type proteins is ~50:50 (38).  In order to 
investigate this supposition using human tissue, and to determine if the decrease in total cMyBP-
C expression is caused by a quantitative decrease in mutant proteins, absolute quantification of 
abundance (AQUA) analysis was performed to determine the relative ratios of mutant and wild-
type proteins in a sample heterozygous for a full length cMyBP-C R495Q missense mutation.   
As shown in Figure 4C this sample contained approximately half the amount of cMyBP-
C expression compared to non-failing donor controls and according to the hypothesis within the 
literature, there should be an equal ratio of mutant and wild type cMyBP-C protein.  To our 
surprise, AQUA analysis showed a 3:1 predominance of the missense protein to its wild-type 
counterpart (Figure 6).  The increase presence of the mutant protein over the wild-type cMyBP-C 
suggests differential stability of the wild-type and mutant protein and/or a competitive advantage 
of the mutant protein over its wild-type counterpart for incorporation into the sarcomere.  
Additional studies are underway to investigate the ratio of mutant and wild-type proteins in 
patients that have other mutations in cMyBP-C, and to compare them to mutations in other 
sarcomere genes, including beta myosin heavy chain, troponin T, tropomyosin, and myosin light 
chain.    
Effects of phosphorylation on cMyBP-C stability: 
A unique feature of cMyBP-C is that it possesses three phosphorylation sites at residues 
Ser-273, Ser-282, and Ser-302 in its M domain.  These sites, which are phosphorylated by PKA 
(all sites) and PKC (only Ser-273 and Ser-302) have been shown to play an important role in 
regulating overall cardiac function and in protecting cMyBP-C against degradation by the UPS 
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(39, 40).  cMyBP-C phosphorylation within HCM samples was studied in samples with cMyBP-
C mutations and non-failing donor controls to investigate if phosphorylation differences could 
explain overall decrease in total cMyBP-C expression and possibly provide insight into the 
observed decrease in UPS activity.  There was no detectable change in the phosphorylation of 
Ser-302 standardized to total cMyBP-C in cMyBP-C mutants compared to non-failing donor 
controls and non-cMyBP-C mutant HCM samples (Figure 7).  One interesting finding was that 
the IVS20 2A>G sample which exhibited the lowest level of overall cMyBP-C expression 
showed the highest level of Ser-302 of any of the samples tested.  Species specificity of 
antibodies directed against phosphorylation at Ser-273 and Ser-282 has hampered studies of 
phosphorylation at these sites.  I plan next to use phosphor-serine specific antibodies to study 
levels of total phosphorylation of cMyBP-C in HCM samples with cMyBP-C mutations 
compared to non-failing control tissue.  
 
PART 1 DISCUSSION: 
 Our study provides direct evidence for the association between ubiquitin proteasome 
dysfunction and two human cardiac pathologies, hypertrophic cardiomyopathy and heart failure.  
Additionally, another important finding in this study is the significant decrease in UPS activity in 
HCM samples that possess pathogenic myofilament gene mutations compared to HCM samples 
that lack gene mutations.  One earlier study described UPS impairment resulted from the 
accelerated degradation of cMyBP-C truncated mutants in an animal model (25), yet limited 
knowledge exists of the effects of myofilament mutations on the UPS activity in human tissue.  
Our study attempts to fill this gap in knowledge by measuring transcript and protein abundance 
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of mutant and wild type versions of cMyBP-C in an attempt to understand potential implications 
on the ubiquitin proteasome system in human tissue and in the pathogenesis of HCM.  
  Investigations of proteasomal activity within F and HCM hearts in comparison to NF 
tissues revealed several important findings.  The most important finding relates to the marked 
inhibition of proteasomal activity of the UPS in F and HCM hearts compared to their non-failing 
counter parts.  This difference in UPS activity is a novel finding that can potentially provide an 
important distinguishing factor between disease states and the non-failing control hearts.  Similar 
to previous reports, polyubiquinated proteins were significantly increased in failing hearts 
compared to non-failing counterparts.  Interestingly, in HCM hearts there was no observed 
increase in polyubiquinated proteins despite a similar reduction in UPS activity.  This difference 
may be attributed to a difference in the duration of UPS dysfunction.   
 A previous explanation for decrease in UPS activity in an animal heart failure model 
included stoichiometric alterations to subunit expression within the 26S complex (7, 46).  
However, in our study we do not see any difference in subunit expression within the 20S 
proteolytic core, 19S regulatory cap, or the 11S activator.  This observation points toward the 
importance of post-translational modification to explain alterations in UPS activity.  A recent 
paper published by our lab shows that oxidative modifications may inhibit the UPS in F tissue, 
but the mechanistic explanation for alterations in UPS activity in HCM tissue has yet to be 
uncovered (24).  
Prior studies on protein degradation in human cardiac disease have been confined to end-
stage heart failure with limited investigation of hypertrophic cardiomyopathy (44).  Over half the 
cases of hypertrophic cardiomyopathy are associated with mutations in sarcomere genes (45). 
We observed that proteasomal activity was significantly lower in patients with sarcomere gene 
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mutations compared to HCM patients without known genetic mutations.  This finding parallels a 
previous animal study that showed truncation mutations in cardiac myosin binding protein C 
contribute to UPS dysfunction in neonatal rate myocytes (25).  In addition, our results show that 
premature truncations, splice site variations, inframe duplications or deletions, and missense 
alleles (Glu542Gln and Arg495Gln) all result in an overall reduction of total cMyBP-C 
expression without a significant change in mRNA expression levels or phosphorylation at Ser-
302 in patients with MYBPC3 mutations.   
An interesting finding of this study was the drastic reduction in cMyBP-C expression in a 
HCM patient (IVS20 2A>G) who progressed to end-stage systolic heart failure and showed the 
highest phosphorylation of Ser-302 per total cMyBP-C expression.  Studies have shown that 
phosphorylation of the cardiac cMyBP-C motif, containing Ser-302, protect cMyBP-C proteins 
from degradation by the ubiquitin proteasome system (40).  Thus, the marked reduction in 
cMyBP-C expression coupled with the significant increase in Ser-302 phosphorylation of IVS20 
2A>G suggest cellular attempts to protect the remaining cMyBP-C from degradation of the UPS, 
possibly contributing to UPS impairment.  
One of the most intriguing finding of this study was the 3:1 predominance of the cMyBP-
C R495Q missence mutant protein over its wild-type counterpart.  Previous studies in vitro and 
in animal models have hypothesized that mutations in myofilament genes that result in premature 
truncations cause haploinsufficiency (35-37), while missense mutations result in an approximate 
50:50 ratio of mutant and wild-type producing a dominant negative effect (38).  Yet, limited 
investigations into the expression of mutant and wild-type proteins have been conducted in 
human tissue.  Our study, with the use of absolute quantification of abundance technology, 
provides the first analysis of the ratio of mutant and wild-type MyBP-C proteins in human 
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cardiac tissue.  This finding is of significant interest as the patient heterozygous for the cMyBP-
C R495Q missense mutation shows an approximate 50% decrease in overall cMyBP-C protein 
expression, yet this expression is not caused by complete degradation of the mutant protein.  
Instead the mutant protein is more highly expressed than its wild-type counterpart.  We 
hypothesize that the decrease in protein expression of cMyBP-C coupled with the predominance 
of the mutant protein may result from differential stability of the mutant and wild-type protein 
possibly through aggregation of the mutant protein which interferes with the basal protein level 
of wild-type cMyBP-C. Immunolocalization and electron microscopic experiments are planned 
to investigate the possibility of protein aggregation and sarcomere disruption.         
In conclusion, a marked decrease in UPS activity is observed in tissue from HCM and F 
patients compared to their NF counterparts.  This decrease cannot be explained by a change in 
subunit expression and thereby suggests the importance of post-translational modifications 
and/or other cellular mechanisms in explaining UPS impairment.  In addition, the presence of 
sarcomere gene mutations in HCM tissue contributes to a more profound inhibition in UPS 
activity then HCM tissue lacking sarcomere mutations and suggests that specific mutations in 
sarcomere proteins, such as cMyBP-C, may interfere with UPS function.  In addition, our 
investigations on samples with cMyBP-C mutations show an overall decrease in protein 
expression without significant changes in mRNA expression levels or phosphorylation at Ser-
302.  Most importantly, quantification of the relative ratio of mutant and wild-type proteins 
suggests that the previous hypothesis developed in animal models of missense mutations in 
myofilament genes resulting in a dominant negative effect with an approximate 50:50 ratio of 
mutant to wild-type proteins may not hold completely true in human disease.    
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PART 2 RESULTS: Alterations in UPS activity in a mouse model of heart failure  
 
Activation of the UPS in mice following left coronary artery ligation (LCA) 
The effects of coronary artery occlusion on peptidase activity of the cardiac proteasome were 
evaluated utilizing an in vivo mouse model in which coronary occlusion was induced by ligating 
the left coronary artery producing a myocardial infarction (MI).  For this model, the infarct size 
was approximately 40% and the survival rate was >70% in young female mice.  Progression to 
heart failure was confirmed by echocardiography, which showed an increase in left ventricle size 
from 2 weeks to 6 months after MI.  Prior to my entry into the lab, Jaime Predmore collected 
hearts 2, 4, and 8 weeks after MI and investigated chymotrypsin-like activity of the UPS within 
these samples across several different ATP concentrations.  Chymotrypsin-like activity was not 
significantly different between Sham and infarcted mice prior to introduction of ATP (Figure 8).  
Upon the addition of ATP, peptidase activity in all samples rose and the ATP-dependent 
chymotrypsin-like activity was significantly higher in infarcted hearts 2, 4, and 8 weeks after 
myocardial infarction compared to Sham operated mice.  As concentrations of ATP were 
increased, chymotrypsin-like activity in all samples was partially inhibited which has been also 
seen in previous studies (41), yet less inhibition occurred in infarcted hearts 2, 4, and 8 weeks 
after MI.   
 
Proteasome subunit composition  
 In an attempt to explain this increase in activation of the UPS 2, 4, and 8 weeks following 
MI, the overall protein expression of representative subunits of the 11S (PA28α), 19S (Rpt4), 
and 20S (α-7) were investigated (Figure 9A and B).  By immunoblotting methodology, there 
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were no significant differences between mice 2, 4, and 8 weeks after MI when compared to their 
Sham counterparts.  Therefore, the inability of differences in proteasomal subunit content to 
explain the observed activation of the UPS points toward the possibility of a post-translation 
modification affecting UPS activity in our mouse model of heart failure.     
 
Purification of the 19S and 20S UPS complexes  
 To gain further insights into potential post-translational modifications of the UPS 
following infarction, I needed to generate a highly purified preparation of the 19S and 20S 
proteasome.  The development of a purification protocol that was both functional and feasible for 
our experimental purposes proved very complicated.  Previous studies have purified the 19S and 
20S complexes using extensive biochemical purification procedures that yield a highly enriched 
sample (8).  For our purposes this procedure was not feasible as it required a significant number 
of mice (100 mice) to produce a single group for comparison.  Thereby, I chose to use an 
immunoprecipatation procedure to purify the UPS complex.  Initially, I attempted to use 
immunoprecipatation columns (Cell Signaling), however these columns did not allow for the co-
immunoprecipatation of subunits from the 19S and 20S complexes from the mouse cardiac 
tissue.  Therefore, I attempted to separately purify the 19S and 20S complexes, however again 
the immunoprecipatation columns failed to allow adequate purification of many subunits within 
each complex.  I then decided to alter my protocol to optimize an immunoprecipatation 
procedure previously used in our lab and separately purify the 19S and 20S complexes using this 
procedure (see methods).  After incorporation of phosphatase inhibitors to allow me to study 
phosphorylation of the UPS complexes following immunoprecipatation in this protocol I was 
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able to achieve a 33 and 30 fold enrichment of the 19S and 20S complexes respectively (Figure 
10A).   
Following the development of this immunoprecipation procedure 2-Dimensional gel 
electrophoresis (2DE) coupled with immunoblot detection was used to further verify the 
purification of proteasomal subunits.  As shown in Figure 10B, subunits within the 20S (α-3) and 
19S (Rpt-4) complexes were separated by 2DE and the identity of these subunits was confirmed 
with immunoblot detection.  The molecule weight and isoelectric points of α-3 (29.47 kDa and 
7.58 pI) and Rpt-4 (44.04 kDa and 7.25 pI) were remarkably consistent with their theoretical 
subunit masses and pI values (www.expasy.org).  One potential problem with my 
immunoprecipation procedure coupled with 2DE analysis was that many additional proteins co-
purified with the proteasomal subunits which may have resulted from proteins binding 
nonspecifically during the immunoprecipatation, proteins functionally associating with the UPS, 
or proteins being in the process of degradation by the UPS (Figure 10B).  However, because of 
this procedure’s ability to identify α-3 and Rpt-4 subunits with immunoblot detection, I chose to 
continue to use this protocol to study post-translational phosphorylation of the proteasomal 
subunits in an attempt to better understand the observed differences in UPS activity between 
Sham and infarcted mice.     
Phosphorylation of the UPS in LCA mice model  
Prior studies have shown the importance of Protein Kinase A (PKA)-dependent 
phosphorylation within the murine cardiac proteasome for both the activation of the proteasome 
and the overall subunit assembly (42, 43).  Following the development of the 
immunoprecipatation procedure, 1-Dimensional gel electrophoresis, 2-Dimensional gel 
electrophoresis (2-DE), and immunoblotting were used to delineate the potential impact of PKA-
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dependent phosphorylation on the 19S and 20S proteasomal complexes.  The 20S complex did 
not react with an antibody designed to recognize PKA dependent phosphorylated substrates (data 
not shown), yet the 19S complex exhibited a prominent band at approximately 50 kDa.  
Comparison of the molecular weight of this PKA substrate reactive protein to the molecular 
weight of several 19S subunits suggests that Rpt-3 may be a phosphorylation target of PKA 
(Figure 11A).  Yet, because of the relatively similar molecular weights of the Rpt-1, Rpt-3, and 
Rpn-5, 2-DE was used to create better subunit separation.  2-DE followed by immunoblotting 
studies suggested that the Rpt-3 subunit may be an endogenous target of PKA-dependent 
phosphorylation (Figure 11B).  However analysis of the potential phosphorylated protein using 
MS/MS revealed that even though this protein aligned precisely with the Rpt-3 specific antibody, 
it was identified as mitochondrial Atp5b ATP synthase subunit beta.  Further studies are 
underway to verify these findings, as the antibody recognition was so precise that it’s possible 
that Atp5b ATP synthase and Rpt 3 could be co-localizing.  Nevertheless, I felt that this 
technique was not going to sufficiently sensitive to detect phosphorylation of proteasome 
subunits and have therefore shifted toward using LC/MS/MS proteomic profiling. 
This new approach allows for a comprehensive proteomic investigation of the UPS in 
Sham and infarcted mice.  With this method, we were able to identify the relative expression of 
all subunits within the 20S complex (α1-α7, β1-β7, and PA200), the 11S complex (Pa28α, 
Pa28β, and Pa28γ), and the 19S complex (Rpt1-Rpt6, Rpn1-3, Rpn5-Rpn9, and Rpn11) except 
Rpn 4, 10, and 12 in hearts taken from both Sham and infarct mice.  There were no significant 
differences in subunit expression in Sham vs. infarct mice confirming our previous 
immunoblotting results on selected subunits (Figure 12A-C).  In addition, we also investigated 
differences in post-translational phosphorylation of the UPS subunits of Sham and infarct 
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through TiO2 enrichment (methods section).  This study showed that the α-7 subunit was 
prominently phosphorylated in both Sham and infarct hearts, however there was no significant 
difference between the two groups (Figure 12D).  This experiment is currently being repeated 
with additional starting material to both confirm the previous result and attempt to increase the 
sensitivity to detect other phosphorylated subunits of the UPS. 
     
PART 2 DISCUSSION:   
 In this study, we show that the development of cardiomyopathy in a myocardial 
infarction mouse model is associated with an increase in activity of the ubiquitin proteasome 
system.  This finding is consistent with an earlier study that described hyperactivation of the 
murine cardiac UPS following aortic constriction (28), but challenges data presented in a similar 
model that suggested an overall decrease in UPS activity contributed to progression to heart 
failure (27).  Another important finding in the present study is that the observed alteration in 
proteasomal activity cannot be explained by differences in the expression of proteasomal 
subunits or the phosphorylation of the α-7 subunit.  
 Our investigation of proteasomal activity revealed several unique findings.  First, there 
was a marked increase in chymotrypsin-like activity in LCA mice 2, 4, and 8 weeks after MI.  
This increase in activity paralleled the remodeling of the heart (49) suggesting that consistent 
over activation of the UPS correlates with the progression of a pathogenic phenotype.  Second, 
our studies also revealed that inhibition of proteasome activity with increasing ATP 
concentrations was attenuated in infarcted mice in contrast to Sham operated mice.  Although a 
similar response of UPS activity to increases in ATP concentrations has been previously 
observed in rat hearts (41), the reason for proteasomal inhibition with increasing concentrations 
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of ATP is currently unknown, but is likely to biologically important given that ATP-dependent 
proteasome activation is altered in pathologic states in both human and mouse cardiomyopathies.  
 Although several previous studies have found alterations in subunit expression 
accompanying variations in UPS activity (46, 47), my comprehensive, proteomics-based 
investigation of the expression of proteasomal subunits did not reveal any differences between 
groups.  The fact that we did not observe differences in proteasomal subunit content between 
Sham and infarcted mice, suggests that post-translational modifications may play a role in 
regulating activity of the ubiquitin proteasome system under pathologic conditions.   
To analyze phosphorylation of the proteasome we pursued a proteomic approach using an 
immunoprecipatation enrichment coupled with 2DE and immunoblot detection.  Although this 
method successfully enriched for the cardiac proteasome and was able to separate and identify 
several proteasomal subunits, it was insufficiently sensitive to study phosphorylation within the 
proteasome due to co-purification of a large number of non-proteasome proteins.  Thereby we 
shifted our approach toward LC/MS/MS proteomic profiling to obtain a comprehensive 
investigation of the UPS and potential phosphorylation differences.  This method proved 
extremely advantageous as it allowed me to identify all proteasomal subunits within the 11S, 
20S, and 19S complexes (except Rpn 4, 10, and 12 within the 19S) further confirming that there 
was no difference in subunit expression between the Sham and infarcted hearts.  In addition, this 
procedure also showed that there was no difference in the phosphorylation of the α-7 subunit in 
Sham and infarcted hearts.  The α-7 subunit is the most heavily phosphorylated subunit of the 
20S proteasome and that its phosphorylation aids in the stabilization of the 26S complex (43).  
The inability to detect differences in α-7 phosphorylation between control and infarcted hearts 
suggests an alternate mechanism for the observed differences in proteolytic activity.   
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In order to determine if the observed increase in proteasome activity reflects a higher 
functioning proteasome, or if the increase in activity is a compensation for inadequate function 
of the UPS to process and degrade substrates, we are collaborating with Dr. XueJun Wang’s 
group (University of South Dakota) on mice engineered with a in vivo reporter for UPS function 
(50). 
In conclusion, a significant increase in the activity of the ubiquitin proteasome system 
was observed following MI.  This increase in activity cannot be explained through alterations in 
the expression of the UPS subunits or alterations in the stability of the 26S proteolytic complex 
resulting from phosphorylation of the α-7 subunit.  Future work will be necessary to uncover the 
mechanistic explanation for the observed increase in UPS activity.  
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Figure 1. Ubiquitin Proteasome System 
 
Configuration of the 26S proteasome and its accompanying subunits that coordinate degradation 













































Figure 2.  UPS activity and accumulation of ubiquinated proteins in NF, HCM, and F 
tissue samples. 
 
A. Heart tissue homogenates (60 µg total cytosolic protein) were assayed for proteasome 
peptidase activity in the presence of increasing concentrations of ATP. Total chymotrypsin-like 
activity represents the difference in fluorescence in the presence and absence of the specific 
inhibitor, lactacystin (18 µmol/L). †P<0.05 for NF (n=6) vs. HCM (n=17). *P<0.01 for NF vs. 
HCM and NF vs. Failing (n=14).  B. Total caspase-like activity represents the difference in 
fluorescence in the presence and absence of the specific inhibitor, ZPNAC (10 µmol/L). *P<0.01 
for NF (n=5) vs. HCM (n=8) and NF vs. Failing (n=8).  Proteasomal activity assays were 
provided by Jaime Predmore.  C. Representative immunoblot of human total protein 
homogenates (50 µg) probed with an antibody against polyubiquinated proteins. D. 
Densitometric analysis for polyubiquinated proteins (>100KDa), standardized to GAPDH as a 















Figure 3. Proteasome subunit protein quantification in human tissue homogenates from 
NF, HCM, and F samples.  Representative immunoblots for the core 20S (α-7), regulatory 19S 
cap (Rpt-1, Rpt-3, Rpt-4, and Rpn-10) and 11S activator (PA28α).  Densiometric analysis of 
subunit expression standardized to GAPDH shows no significant difference in expression 
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Figure 4. Effects of Sarcomere Mutant Expression, specifically cMyBP-C mutations, on the 
UPS  
A. Comparison of chymotrypsin-like activity in samples from HCM patients with or without 
sarcomere gene mutations. *P<0.05 for mutation positive (n=6) vs. mutation negative (n=7).  C.  
Representative immunoblot comparing expression of total cMyBP-C in heart tissue from HCM 
patients in whom no sarcomere mutations were identified by clinical genetic testing, patients 
with non-MyBPC3 sarcomere mutations, patients with MyBPC3 mutations, and non-failing 
donors as controls. As previously reported, no truncated mutant cMyBP-C mutant proteins were 
detected.  D. Densitometric analysis of cMyBP-C expression, relative to GAPDH as a loading 
control and expressed as a percentage of a single control sample (*). There was a significant 
decrease in total MyBP-C expression in HCM tissue samples with MyBPC3 mutations compared 
to HCM samples that did not have MyBPC3 mutations (P<0.01) and control tissue (P<0.05).  # 
IVS20 2A>G was from the apex of a patient who underwent left ventricular assist device 
implantation for end stage systolic heart failure.   E. Densitometric analysis of cMyBP-C 
expression, relative to GAPDH as a loading control, in non-failing donors as controls vs. patients 
with end-stage heart failure.  cMyBP-C levels were not significantly reduced (p=0.44) in samples 





































Figure 5.  Quantification of mRNA transcripts in HCM tissue with cMyBP-C mutations 
and non-failing donor control.  Hydrolysis probe analysis of mRNA expression relative to β-
actin as an endogenous referent in non-failing donor control samples and tissue HCM containing 
cMyBP-C mutations gene.  The results are expressed as a percentage of the average expression 
of the two control samples with intra-assay standard error within each sample shown as error 
bars. There was no significant decrease (p=0.317) in cMyBP-C mRNA expression from HCM 





















Figure 6. Absolute quantification of abundance (AQUA) methodology used to compute the 
stoichiometric ratios of full length mutant proteins relative to wild-type for cMyBP-C 
R495Q. Wild-type and mutant AQUA peptides were synthesized using heavy K isotopes as 
described in the methods section. Endogenous cMyBP-C proteins from human HCM hearts were 
gel extracted and digested with Lys-C. Peptide mixtures were spiked with 2µL of 10 fmol/µL 
solution of the corresponding AQUA peptides and analyzed in duplicate by LC/SRM. Peak areas 
were calculated using the Thermo Qual Browser Software. Peak areas for endogenous peptides 
were divided by peak areas of AQUA peptides to yield a relative mole ratio of endogenous 

































Figure 7. Phosphorylation of cMyBP-C at Ser-302 shows no significant difference. 
Representative immunoblot of phosphorylated cMyBPC at Ser-302 in HCM tissue samples 
containing MYBPC3 mutations, HCM tissue samples lacking sarcomere mutations, HCM tissue 
with non-MYBPC3 sarcomere mutations and control tissue.  Densitometric analysis of phospho-
cMyBP-C expression was calculated relative to GAPDH as a loading control and expressed as a 
ratio of total cMyBP-C. There was no significant difference in pSer302 detection among the 
groups.   Antibodies against phospho-serine 273 and phospho-serine 282 of cMyBP-C were not 































Figure 8. Chymotrypsin-like activity in sham vs. infarcted (MI) mouse hearts. 
Chymotrypsin-like activity is calculated as the difference in fluorescence in the presence and 
absence of lactacystin (18 µmol/L), a specific inhibitor of chymotrypsin-like activity.  Sham 
(n=25, pooled) and MI (n=3 per group).  *Overall P<0.05 for the difference between sham and 
























Figure 9. Proteasome subunit protein quantification in mouse whole heart homogenates. A. 
Representative immunoblots probed for proteasome subunits from the 20S core (α-7), 19S 
regulatory cap (Rpt 4), and 11S activator (PA28α) (top).  B. Densitometric analysis of subunit 
protein content relative to GAPDH as a protein loading control (bottom). There were no 

























Figure 10. Immunoprecipatation of murine cardiac UPS and analysis via 2-Dimensional gel 
electrophoresis. A. Representative immunoblots of 15 µg of whole-heart homogenate or elution 
product from immunoprecipatation protocol probed with antibodies against Rpt-6 for the 19S 
complex and α-3 for the 20S complex. B. 2DE of purified 19S and 20S complex stained with 
SYPRO RUBY stain for total protein.  The panels on the right correspond to representative 
immunoblots of 2-Dimnesional separation of the UPS probed with antibodies designed to 
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recognize Rpt-4 or α-3.  Images of these blots were overlaid onto the protein stained gel to locate 


















































Figure 11. Detection of PKA-dependent phosphorylation of UPS subunits. A.  
Representative immunoblots of 15 µg of the purified 19S complex probed with an antibody 
against PKA-dependent phosphorylation that was subsequently stripped and reprobed for 
specific 19S subunits.  B.  Representative immunoblot of a 2-DE probed with an antibody 
against PKA-dependent phosphorylation and subsequently stripped and reprobed with a Rpt-3 
specific antibody.  The spots on a SYPRO RUBY stained 2DE corresponding to location of the 
Rpt-3 and PKA antibody detection were gel excised and found to be mitochondrial Atp5b ATP 







Figure 12. LC/MS/MS proteomic profiling of UPS subunits and phosphor analysis of α-7 
subunit in sham vs. infarct mice. A.  Quantification of the spectral counts obtained from 
LC/MS/MS analysis for subunits from the 20S complex in Sham vs. LCA infarct tissue relative 
to TnI as a control (n=3 per group).  Statistical analysis revealed no significant difference in any 
of the subunits within the 20S complex in Sham vs. infarcted mice.  B.  LC/MS/MS analysis for 
subunits of the 19S complex in Sham vs. LCA infarct tissue standardized to actin as a control 
(n=3 per group) demonstrated no significant difference subunit expression within the 19S 
complex.  C. Quantification of the spectral counts obtained from LC/MS/MS analysis for 
subunits from the 11S complex in Sham vs. LCA infarct relative to TnI as a control (n=3 per 
group).  Statistical comparison showed there to be no difference in subunit expression between 
the groups in question.  D.  Quantification of phosphorylated α7 based on LC/MS/MS spectral 
counts expressed as a ratio to total α7 in Sham vs. LCA infarct.  Statistical analysis showed no 
significant difference in phosphorylation of α7 between the two groups (p= 0.488).  
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